10Dec 2022
Safety and efficacy of an oral insulin (Capsulin) in patients with early‐stage type 2 diabetes: A dose‐ranging phase 2b study

Safety and efficacy of an oral insulin (Capsulin) in patients with early‐stage type 2 diabetes: A dose‐ranging phase 2b study

To compare the pharmacodynamic properties of different doses of regular human insulin administered in capsule form twice daily in a randomised twelve‐week open‐label study. The study met its primary clinical endpoint of a decrease in HbA1c of 0.5% or higher in the dose group receiving 150 iu BD. No serious treatment‐related adverse events were recorded, and no incidence of hypoglycaemia was reported throughout the entire 12‐week study period. Capsulin oral insulin administered twice per day at a dose of 150 iu per capsule is safe, with no confirmed treatment‐linked hypoglycaemic events, and results in significant decreases from baseline in HbA1c, FPG and triglycerides.

  • #endo-diabetology

Like

Save

Share